On August 29th, 2023, Professor Qian Yingyi, Chairman of the Council of Westlake University and renowned economist, led a delegation to conduct an on-site inspection of Westlake Pharmaceuticals, engaging in discussions and exchanges with the company's research and development personnel.

As an innovative biomedical enterprise incubated by Westlake University, Westlake Pharmaceuticals represents a valuable exploration in translating scientific findings into industrial achievements. Now the company has made commendable breakthroughs. Mprosevir, an originally discovered, novel-structured, broad-spectrum oral small molecule antiviral drug against coronaviruses, which has completed its Phase III clinical studies and is set to file a drug marketing application with National Medical Products Administration in the near future.

Simultaneously, Westlake Pharmaceuticals has assembled a top-notch research and development team headed by world-class scientists, with over 75% of its employees holding degrees from prestigious domestic and overseas institutions.

Professor Qian Yingyi and his delegation began their visit by touring the research and development environment at Westlake Pharmaceuticals, visiting departments specializing in biological research, chemical synthesis, and AI-assisted drug design, gaining an in-depth understanding of how the R&D team collaborates closely to complete the entire process of developing an innovative drug from scratch.

During the tour, Professor Qian paid particular attention to Westlake Pharmaceuticals' first product, Mprosevir. He mentioned the famous "Thirty Percent Rule" in the pharmaceutical industry, stating that the development of a new drug often requires a decade of work, costs ten billion US dollars, and has only a 10% success rate. Westlake Pharmaceuticals broke this industry norm by advancing the original drug Aprisivir from the initial research phase to clinical trials within just three years, an achievement worthy of admiration.

Dr. Liang Dongdong, the Director of Research and Development at Westlake Pharmaceuticals, provided a detailed account of the entire development process for Aprisivir. "Led by several top-notch scientists, Westlake Pharmaceuticals has managed to successfully translate cutting-edge research findings into practical applications, which has been the key to defying the 'Thirty Percent Rule.'"

Finally, Professor Qian Yingyi took a cordial group photo with the company staff and encouraged everyone to continue their diligent efforts and strive for constant breakthroughs, aiming to develop more and better original innovative drugs.